Ensign Peak Advisors’s First Tracks Biotherapeutics TRAX Stock Holding History
Bought
Maintained
Sold
Other funds holding TRAX
Ensign Peak Advisors's TRAX Position: Q3 2026 in Review
Ensign Peak Advisors reduced its First Tracks Biotherapeutics (TRAX) stake by 16% in Q3 2026, selling an estimated $744K and leaving 96,936 shares worth $3.44M. The position accounts for 0.01% of the portfolio, ranked #649.
Ensign Peak Advisors first reported a position in TRAX in Q2 2026 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.
- Ensign Peak Advisors held 96,936 shares of First Tracks Biotherapeutics worth $3.44M as of Q3 2026.
- Ensign Peak Advisors sold 19,042 First Tracks Biotherapeutics shares in Q3 2026, an estimated $744K.
- First Tracks Biotherapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #649 holding.
- Ensign Peak Advisors first reported a position in First Tracks Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
- 182 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.
Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.